On October 26, 2023, Tempest Therapeutics Received A Formal Notification From The Nasdaq That The Company Has Regained Compliance With Nasdaq $1.00 Minimum Price Rule
Portfolio Pulse from Charles Gross
Tempest Therapeutics has regained compliance with Nasdaq's $1.00 minimum price rule, according to a formal notification from Nasdaq on October 26, 2023.
October 30, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tempest Therapeutics' stock has regained compliance with Nasdaq's minimum price rule, which could potentially boost investor confidence.
Regaining compliance with Nasdaq's minimum price rule is a positive development for Tempest Therapeutics. It removes the risk of delisting, which can be a significant concern for investors. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100